FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, and represents humanised anti-CD40-antibodies and their antigen-binding fragments, and also polynucleotides coding variable regions of the antibodies under the invention. Also, the pharmaceutical composition and a set on the basis of the specified antibodies are presented.
EFFECT: antibodies under the invention can be used effectively for treating a disease characterised by CD40 antigen expression.
25 cl, 5 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| ANTI-CLUSTERIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND THEIR USE FOR TUMOURS VOLUME REDUCTION | 2010 |
|
RU2627163C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| HUMANISED ANTI-TGF-BETA-ANTIBODY | 2005 |
|
RU2386638C2 |
| ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | 2018 |
|
RU2812915C2 |
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| ANTI-CD40-ANTIBODIES, APPLICATION AND METHODS | 2012 |
|
RU2649055C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
